

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Application .....	200	1	24	4,800
Estimated Total Annual Burden Hours .....				4,800

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above.

Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication

Dated: September 4, 2002.

**Robert Sargis,**

*Reports Clearance Officer.*

[FR Doc. 02-22852 Filed 9-9-02; 8:45 am]

BILLING CODE 4184-01-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. 98D-0834]

**Withdrawal of Guidances on Estrogen and Estrogen/Progestin-Containing Drug Products**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; withdrawal.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the withdrawal of two guidances: A draft entitled "Labeling Guidance for Noncontraceptive Estrogen Drug Products—Prescribing Information for Healthcare Providers and Patient Labeling" and a final "Guidance for Clinical Evaluation of Combination Estrogen/Progestin-Containing Drug Products Used for Hormone Replacement Therapy of Postmenopausal Women." These guidances are under agency review for change.

**DATES:** General comments on agency guidance documents are welcome at any time.

**ADDRESSES:** Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/ecomments>.

Submit written requests for the guidance to the Division of Drug Information (HFD-240), Center for Drug Evaluation and Research (CDER), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. See the **SUPPLEMENTARY INFORMATION** section for electronic access to agency guidance documents.

**FOR FURTHER INFORMATION CONTACT:** Dan Shames, Center for Drug Evaluation and Research (HFD-580), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4260

**SUPPLEMENTARY INFORMATION:** FDA is announcing the withdrawal of two guidances on estrogen and estrogen/progestin drug products. The two guidances being withdrawn are the draft guidance "Labeling Guidance for Noncontraceptive Estrogen Drug Products—Prescribing Information for Healthcare Providers and Patient Labeling" (labeling guidance) and the final "Guidance for Clinical Evaluation of Combination Estrogen/Progestin-Containing Drug Products Used for Hormone Replacement Therapy of Postmenopausal Women" (combination guidance). The draft labeling guidance was made available for comment in the

**Federal Register** of September 27, 1999 (64 FR 52100); the final combination guidance was made available in March 1995. Both guidances are undergoing review for change as a result of the results from the National Institutes of Health (NIH) Women's Health Initiative trial.<sup>1</sup>

Interested persons may submit written or electronic comments to the Dockets Management Branch (see **ADDRESSES**). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Persons with access to the Internet may obtain CDER guidance documents at <http://www.fda.gov/cder/guidance/index.htm>.

Dated: August 27, 2002.

**Margaret M. Dotzel,**

*Associate Commissioner for Policy.*

[FR Doc. 02-22900 Filed 9-9-02; 8:45 am]

BILLING CODE 4160-01-S

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Health Resources and Services Administration**

**Agency Information Collection Activities: Submission for OMB Review; Comment Request**

Periodically, the Health Resources and Services Administration (HRSA) publishes abstracts of information collection requests under review by the Office of Management and Budget, in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request a copy of the clearance requests submitted to OMB for review, call the HRSA Reports Clearance Office on (301) 443-1129.

<sup>1</sup> The results of the NIH Women's Health Initiative trial were reported in the *Journal of the American Medical Association*, 2002;288:321-333.